ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia
- Proven excellent therapeutic effect with 60% objective response rate and 100% complete remission in…
- Proven excellent therapeutic effect with 60% objective response rate and 100% complete remission in…
SEOUL, South Korea--(BUSINESS WIRE)--#BLUEHB--TVM CEO Sisley L. visited Seville, Spain after being invited to a…
The Independent Collection is set to maintain strong growth with luxury and lifestyle experiences CHICAGO--(BUSINESS…
Extends IP and production pipeline through significant acquisitions and partnerships with entertainment and webtoon production…
Email Contact@flashlightcap.com to Register and Visit www.FlashlightCap.com to Learn How We Plan to Help Deliver…
WALL, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), an innovative…
New office and expansion of leadership team enables the leading incident response and cyber security…
The Copernicus Masters announced this year’s Japan regional competition winner — Tenchijin, a JAXA (Japan…
FRANKFURT AM MAIN, Germany--(BUSINESS WIRE)--#IEEE--China’s massive investment in industrial robotics has put the country in…
HONG KONG--(BUSINESS WIRE)--Since the launch of counterfeiting action by ELFBAR in June 2021, it has…